Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Treatment Reviews is Scopus-indexed (Q1, CiteScore 17.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by W.B. Saunders Ltd.
Checked against the index lists dated .
ISSN 0305-7372Verify ISSN ↗1532-1967Verify ISSN ↗
Publisher: W.B. Saunders Ltd
Cost to publish: About US$4,910 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 6 / 361 | 98th | Q1 |
| Oncology | 23 / 428 | 94th | Q1 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1993–present (also 1974–1991), best quartile Q1, CiteScore 17.7.
Cancer Treatment Reviews is Q1 in Radiology, Nuclear Medicine and Imaging (rank 6 of 361) and Q1 in Oncology (rank 23 of 428), by CiteScore 2025.
Cancer Treatment Reviews is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 17.7, which places it in quartile Q1 at the 98th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 3.745, quartile Q1, with an H-index of 180.
The publisher lists an article processing charge of about US$4,910 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Cancer Treatment Reviews is published by W.B. Saunders Ltd. Its print ISSN is 0305-7372 and its online ISSN is 1532-1967.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Treatment Reviews has an h-index of 206 and a 2-year mean of 10.11 citations per paper (OpenAlex). Its Scopus CiteScore is 17.7, quartile Q1. On 2-year citations it ranks #4 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Cancer Treatment Reviews published 136 papers in 2025; its busiest recent year was 2018 with 144. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 98 research articles (2025–2026), authors are most often from Italy (23.3%), United States (12.6%) and France (10.4%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.